Abstract:Comparative genomic in situ hybridization (CGH) provides a new possibility for searching genomes for imbalanced genetic material. Labeled genomic test DNA, prepared from clinical or tumor specimens, is mixed with differently labeled control DNA prepared from cells with normal chromosome complements. The mixed probe is used for chromosomal in situ suppression (CISS) hybridization to normal metaphase spreads (CGH-metaphase spreads). Hybridized test and control DNA sequences are detected via different fluorochromes, e.g., fluorescein isothiocyanate (FITC) and tetraethylrhodamine isothiocyanate (TRITC). The ratios of FITC/TRITC fluorescence intensities for each chromosome or chromosome segment should then reflect its relative copy number in the test genome compared with the control genome, e.g., 0.5 for monosomies, 1 for disomies, 1.5 for trisomies, etc. Initially, model experiments were designed to test the accuracy of fluorescence ratio measurements on single chromosomes. DNAs from up to five human chromosome-specific plasmid libraries were labeled with biotin and digoxigenin in different hapten proportions. Probe mixtures were used for CISS hybridization to normal human metaphase spreads and detected with FITC and TRITC. An epifluorescence microscope equipped with a cooled charge coupled device (CCD) camera was used for image acquisition. Procedures for fluorescence ratio measurements were developed on the basis of commercial image analysis software. For hapten ratios 4/1, 1/1 and 1/4, fluorescence ratio values measured for individual chromosomes could be used as a single reliable parameter for chromosome identification. Our findings indicate (1) a tight correlation of fluorescence ratio values with hapten ratios, and (2) the potential of fluorescence ratio measurements for multiple color chromosome painting. Subsequently, genomic test DNAs, prepared from a patient with Down syndrome, from blood of a patient with T-cell prolymphocytic leukemia, and from cultured cells of a renal papillary carcinoma cell line, were applied in CGH experiments. As expected, significant differences in the fluorescence ratios could be measured for chromosome types present in different copy numbers in these test genomes, including a trisomy of chromosome 21, the smallest autosome of the human complement. In addition, chromosome material involved in partial gains and losses of the different tumors could be mapped to their normal chromosome counterparts in CGH-metaphase spreads. An alternative and simpler evaluation procedure based on visual inspection of CCD images of CGH-metaphase spreads also yielded consistent results from several independent observers. Pitfalls, methodological improvements, and potential applications of CGH analyses are discussed.

Development Of A Focused Oligonucleotide-Array Comparative Genomic Hybridization Chip For Clinical Diagnosis Of Genomic Imbalance

Analytical and clinical validity of whole-genome oligonucleotide array comparative genomic hybridization for pediatric patients with mental retardation and developmental delay.

Using SNP array to identify aneuploidy and segmental imbalance in translocation carriers.

Oligonucleotide Microarrays for Clinical Diagnosis of Copy Number Variation

Genome-wide oligonucleotide array comparative genomic hybridization for etiological diagnosis of mental retardation: a multicenter experience of 1499 clinical cases.

Clinical implementation of whole-genome array CGH as a first-tier test in 5080 pre and postnatal cases

Clinical Application of Chromosome Microarray Analysis in Han Chinese Children with Neurodevelopmental Disorders

A prenatal missed diagnosed case of submicroscopic chromosomal abnormalities by karyotyping: the clinical utility of array-based CGH in prenatal diagnostics.

[Application of Single Nucleotide Polymorphism Microarray in Clinical Diagnosis of Intellectual Disability or Retardation].

Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization

High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays

Standardization and Diversification of Copy Number Microarray Testing for Clinical Diagnostics—Implications of the Cross-Platform/Algorithm Study on Clinical Diagnostic Chromosomal Microarray Analysis

Technology-Driven and Evidence-Based Genomic Analysis for Integrated Pediatric and Prenatal Genetics Evaluation

Array-based Comparative Genomic Hybridization for Detecting Children with Mental Retardation and Congenital Multi-Malformations

Detection Of Genomic Imbalances By Comparative Genomic Hybridization In Chinese Fetuses With Malformations

Chromosomal Aberrations in Pediatric Patients with Moderate/Severe Developmental Delay/Intellectual Disability with Abundant Phenotypic Heterogeneities: A Single-center Study

[Array comparative genomic hybridization detection of a de novo 4q21.21-q22.1 deletion in a child with severe growth retardation].

A novel competitive fluorescent multiplex STR polymorphism assay for rapid, reliable and single-tube screening of 22q11.2 copy-number aberrations.

[The Diagnostic Value of Chromosome Microarray Analysis Technique in the Genetic Causes of Children with Intellectual Disability or Global Developmental Delay].

Detection of Aneuploidy from Single Cells by Array-Comparative Genetic Hybridization

Clinical Diagnosis of Genetic Disorders at Both Single-Nucleotide and Chromosomal Levels Based on BGISEQ-500 Platform